Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
28 mars 2025 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled for...
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update
11 mars 2025 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study Fast Track Designation granted by FDA for CRB-701 to treat metastatic cervical cancerCRB 913 SAD/MAD obesity...
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
25 févr. 2025 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer...
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025
14 févr. 2025 07h30 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Study mirrored 4 highest doses used in China dose escalation study presented at ASCO 2024 Safety, tolerability and PK comparable to China dataset with no DLTs observed in either study Low levels of...
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU
11 févr. 2025 07h30 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the abstract for its first-in-human dose...
Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference
28 janv. 2025 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer...
Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025
08 janv. 2025 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced data from its first-in-human dose escalation...
Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer...
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors
09 déc. 2024 07h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio,...
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
03 déc. 2024 07h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio,...